Document is current
Any future updates will be listed below
-
Authors
Han, Seungbin https://orcid.org/0000-0003-1117-3102
Haertle, Larissa https://orcid.org/0000-0002-3927-9163
Munawar, Umair
Truger, Marietta
Hainold, Ann-Sophie
Lee, Chien-Yun
Kurian, Shilpa
Verbruggen, Christina
Nerreter, Silvia
Vogt, Cornelia
Besant, Emma
Rein, Nina
Lehmann, Johanna
Köppel, Max
Tamamushi, Yoko
Zhou, Xiang
Steinbrunn, Torsten
Haaf, Thomas
Küster, Bernhard
Slaby, Ondrej
Haferlach, Claudia
Einsele, Hermann
Rasche, Leo
Waldschmidt, Johannes https://orcid.org/0000-0001-5340-1818
Besse, Andrej https://orcid.org/0000-0003-0047-2959
Driessen, Christoph https://orcid.org/0000-0002-1124-7303
Besse, Lenka https://orcid.org/0000-0003-4739-7618
Kortüm, K. Martin
-
Funding
Funding for this research was provided by:
Universitätsklinikum Würzburg
- License Information
-
More Information
Article History
Received: 3 July 2025
Accepted: 13 March 2026
First Online: 1 April 2026
Declarations
:
: The study was approved by the independent Cantonal Ethical Committee (EKOS09/057) and by the Ethical Committee of Wuerzburg University (No. 8/21). All patients provided written informed consent.
: Not applicable. No identifiable patient data are presented in this study.
: J.W. has received personal fees from GSK, Menarini-Stemline, Pfizer, Takeda, Sanofi, Oncopeptides, Janssen, and Skyline Dx, as well as research support from BMS. H.E. reports grant funding and other support from Sanofi, Takeda, Novartis, BMS, GSK, Amgen, and Janssen. C.H. is a shareholder in and employee of MLL Munich Leukemia Laboratory. L.R. has received personal fees from Sanofi, Amgen, GSK, Janssen, Pfizer, and BMS. K.M.K. reports personal fees from GSK, Takeda, AbbVie, Celgene, and BMS, and has also received both grants and personal fees from Janssen. All remaining authors declare no competing interests.
